BFA
CLDX icon

BlackRock Fund Advisors’s Celldex Therapeutics CLDX Stock Holding History

BlackRock Fund Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$16.2M Buy
305,848
+36,842
+14% +$2.1M ﹤0.01% 2296
2016
Q3 		$16.3M Buy
269,006
+17,849
+7% +$1.11M ﹤0.01% 2174
2016
Q2 		$16.5M Buy
251,157
+11,135
+5% +$707K ﹤0.01% 2129
2016
Q1 		$13.6M Buy
240,022
+987
+0.4% +$111K ﹤0.01% 2199
2015
Q4 		$56.2M Sell
239,035
-11,759
-5% -$2.56M 0.01% 1395
2015
Q3 		$39.7M Buy
250,794
+8,140
+3% +$2.3M 0.01% 1572
2015
Q2 		$91.8M Sell
242,654
-5,272
-2% -$2.09M 0.02% 1066
2015
Q1 		$104M Buy
247,926
+25,144
+11% +$8.99M 0.02% 969
2014
Q4 		$61M Buy
222,782
+20,500
+10% +$5.1M 0.02% 1322
2014
Q3 		$39.3M Sell
202,282
-1,568
-0.8% -$342K 0.01% 1515
2014
Q2 		$49.9M Sell
203,850
-19,487
-9% -$4.4M 0.01% 1392
2014
Q1 		$59.2M Buy
223,337
+13,410
+6% +$5.13M 0.02% 1289
2013
Q4 		$76.2M Buy
209,927
+10,869
+5% +$4.19M 0.02% 1054
2013
Q3 		$106M Buy
199,058
+25,596
+15% +$8.78M 0.04% 706
2013
Q2 		$40.6M Buy
+173,462
New +$34.2M 0.01% 1378

Other funds holding CLDX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

BlackRock Fund Advisors's CLDX Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Celldex Therapeutics (CLDX) stake by 14% in Q4 2016, buying an estimated $2.1M and bringing the position to 305,848 shares worth $16.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2296.

BlackRock Fund Advisors first reported a position in CLDX in Q2 2013 and has held it in 15 quarters since. The position peaked at $106M in Q3 2013. 140 funds tracked by Wall St. Rank hold CLDX as of Q4 2016.

  • BlackRock Fund Advisors held 305,848 shares of Celldex Therapeutics worth $16.2M as of Q4 2016.
  • BlackRock Fund Advisors bought 36,842 Celldex Therapeutics shares in Q4 2016, an estimated $2.1M.
  • Celldex Therapeutics made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2296 holding.
  • BlackRock Fund Advisors first reported a position in Celldex Therapeutics in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Fund Advisors's Celldex Therapeutics position peaked at $106M in Q3 2013.
  • 140 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.